Literature DB >> 21969847

Surgery for high-risk localized prostate cancer.

Jan Schmitges1, Quoc-Dien Trinh, Jochen Walz, Markus Graefen.   

Abstract

Treatment of men with high-risk prostate cancer (PCa) remains challenging for urologists. The complex natural history of high-risk PCa and the lack of specific and accurate definitions for high-risk disease impede treatment decision making. Historically, surgery in this patient group has been avoided based on the perception of ostensibly higher complication rates associated with inferior functional and oncological outcomes. To date, no randomized data comparing different therapy approaches have been made available. Several investigators have reported that continence rates in patients after radical prostatectomy (RP) for high-risk disease seem to be unaffected. Similarly, in a large proportion of these men, a nerve-sparing procedure can be performed without a significant negative impact on surgical margin rates and with comparable potency results. Moreover, extended pelvic lymph node dissection (EPLND) contributes to accurate pathological staging with a marginal effect on perioperative morbidity. With regards to the benefits of RP on local recurrence and cure rates, realistic expectations regarding the success of RP alone or in the context of a multimodal approach should be provided during patient counseling.

Entities:  

Keywords:  high-risk prostate cancer; perioperative complications; prostatectomy; urinary incontinence

Year:  2011        PMID: 21969847      PMCID: PMC3175701          DOI: 10.1177/1756287211418722

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  73 in total

1.  Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer.

Authors:  H Van Poppel; H Goethuys; P Callewaert; L Vanuytsel; W Van de Voorde; L Baert
Journal:  Eur Urol       Date:  2000-10       Impact factor: 20.096

2.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

5.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Authors:  Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

6.  Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy.

Authors:  Phillip M Pierorazio; Benjamin A Spencer; Tara R McCann; James M McKiernan; Mitchell C Benson
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

7.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

Authors:  Ofer Yossepowitch; Scott E Eggener; Angel M Serio; Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  Eur Urol       Date:  2007-10-12       Impact factor: 20.096

Review 9.  Role of radical prostatectomy in the treatment of high-risk prostate cancer.

Authors:  Ofer Yossepowitch; James A Eastham
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

10.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; M Schnall; J E Tomaszewski; A Wein
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

View more
  7 in total

1.  Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy.

Authors:  Anup Kumar; Srinivas Samavedi; Anthony S Bates; Vladimir Mouraviev; Rafael F Coelho; Bernardo Rocco; Vipul R Patel
Journal:  J Robot Surg       Date:  2016-07-19

Review 2.  The status of surgery in the management of high-risk prostate cancer.

Authors:  Christian Bach; Sailaja Pisipati; Datesh Daneshwar; Mark Wright; Edward Rowe; David Gillatt; Raj Persad; Anthony Koupparis
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

3.  Racial disparities in operative outcomes after major cancer surgery in the United States.

Authors:  Shyam Sukumar; Praful Ravi; Akshay Sood; Mai-Kim Gervais; Jim C Hu; Simon P Kim; Mani Menon; Florian Roghmann; Jesse D Sammon; Maxine Sun; Vincent Q Trinh; Quoc-Dien Trinh
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

4.  Is radical prostatectomy a useful therapeutic option for high-risk prostate cancer in older men?

Authors:  Markus Graefen; Thorsten Schlomm
Journal:  Oncologist       Date:  2012

5.  High resolution ultrasound features of prostatic rib metastasis: a prospective feasibility study with implication in the high-risk prostate cancer patient.

Authors:  Kenneth S Lee; Arthur A De Smet; Glenn Liu; Mary Jane Staab
Journal:  Urol Oncol       Date:  2013-03-06       Impact factor: 3.498

6.  Lower urinary tract symptoms (LUTS) before and after robotic-assisted laparoscopic prostatectomy: does improvement of LUTS mitigate worsened incontinence after robotic prostatectomy?

Authors:  Lukas Dommer; Jan A Birzele; Khosrow Ahmadi; Mario Rampa; Daniel J Stekhoven; Räto T Strebel
Journal:  Transl Androl Urol       Date:  2019-08

7.  Novel epigenetic target therapy for prostate cancer: a preclinical study.

Authors:  Ilaria Naldi; Monia Taranta; Lisa Gherardini; Gualtiero Pelosi; Federica Viglione; Settimio Grimaldi; Luca Pani; Caterina Cinti
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.